Heparin Market Forecasts from 2023 to 2028

The heparin market was valued at US$5.256 billion in 2021 and is expected to grow at a CAGR of 5.81% during the forecast period.

Heparin prevents blood clotting in the body and acts as an anticoagulant used in medicines, blood specimens, and kidney dialysis machines. The rising prevalence of cardiovascular diseases leading to more surgeries is expected to propel the heparin market size. Moreover, the aging population is more prone to atrial fibrillation and with a more aging population, there is an anticipated growth of the heparin market globally. Additionally, its wider application coupled with government investments and research initiatives is further expected to bolster the heparin market size during the forecaster period.

MARKET DRIVERS:

Wider application in surgeries to drive the demand for heparin.

Heparin is beneficial in a range of health-related problems, and it is often given after surgery to blood from clotting. It is used in bypass surgery, open-heart surgery, kidney dialysis and reduces the risk of pulmonary embolism. For example, Lovenox, a low molecular weight heparin is used frequently after surgery in the form of injection. Moreover, it treats a serious blood condition called disseminated intravascular coagulation. These phenomenal after-surgery benefits of heparin are expected to boost the heparin market size in the coming years.

Rising prevalence of cardiovascular diseases to fuel the market growth

Heparin is used as an anticoagulant after open-heart surgery and thus, the rising cardiovascular cases particularly atrial fibrillation and heart attacks are a major growth driver of the heparin market. According to the data by National Library of Medicine, National Centre for Biotechnology Information, around 37 million people have atrial fibrillation in February 2021 with a prevalence rate of 33% in the last 20 years. According to CDC US, nearly 12 million people are estimated to have atrial fibrillation in the US by 2030. Moreover, atrial fibrillation was the cause of more than 26000 deaths in the US in 2019 as per the CDC US. The risk factors of atrial fibrillation are heart failure, diabetes, obesity, high blood pressure, chronic kidney disease, and others. These rising cases along with their adverse effect contemplated bolstering the heparin market size.

Rising Aging Population to further accelerate the market expansion.

The aging population is more prone to health problems, atrial fibrillation, and fractures, thus leading to more surgeries thereby propelling the heparin market. According to WHO, there were more than 1 billion people aged 60 or above which is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. Moreover, the pace of population aging is much faster now as compared to the past as per the WHO. By 2030, 1 in 6 people will be aged 60 or above and the number of people aged 80 or above is expected to triple by 2050 thereby reaching 426 million. According to the National Institute of Aging, people aged 65 or above are more likely to get a heart attack or stroke as compared to younger people thus the aging population indicates more surgeries. All these factors are anticipated to widen the demand for heparin thereby increasing the heparin market size.

Opportunities in the Heparin Market

The heparin market is growing due to the rising health problems and particularly cardiovascular diseases providing a good opportunity to enter the heparin market. Further, recent research, experiments, and government initiatives in the field are expected to boost the heparin market. For instance, the Indian government allowed the import of raw material for manufacturing crude heparin to treat covid-19 patients and it will further prospect the heparin market growth in the nation for future use. Furthermore, the major players may see to launch more innovative and efficient heparin solutions in the coming years thereby widening the heparin market scope.

MARKET RESTRAINTS:

Overdose of heparin lead to unfavourable side effects.

Heparin is subject to an individual’s need based on weight, immunity, and blood thickness. The excess of heparin dose may decrease the platelet level known as heparin-induced thrombocytopenia (HIT) which can eventually lead to blood clots in veins. The heparin dose must be given by skilled and expert doctors and in low-income and poor countries with an average healthcare system and lack of skilled doctors, the heparin market shows a stagnant usage thereby a major restraint in the heparin market. Moreover, heparin may cause serious bleeding and may take longer to stop bleeding and may cause rare deaths. Additionally, the strict health regulations and government guidelines for heparin usage are also considered a restraint in the heparin market growth.

North America is expected to be a significant marketplace

The North American region is expected to hold a significant share of the global heparin market during the forecasted period. Various factors contributing to such a significant share are technological advancements, rising cardiovascular diseases, and the presence of a strong healthcare system coupled with better technological and research innovations. According to the American Medical Association, the healthcare system share of the US in the nation’s GDP was 18.3% in 2021 which is far higher than other nations. Moreover, the health care spending increased by 2.7% in 2021 in the US which indicates of enhanced healthcare system in the region. Additionally, the aging population in the region coupled with more adoption of modernization is anticipated to boost the heparin market in the region.

Heparin Market Players

• LEO Pharma A/Sis a multinational company providing solutions in medical dermatology. The products offered by the company are Heparin LEO®, innohep® Protopic®, Fucibet® including others.
• Sanofiis a global innovative healthcare company with a focus to improve people’s lives by chasing miracles of science. The company offers Clexane®, low molecular weight heparin with four sizes – 20mg/0.2ml, 40mg/0.4ml, 60mg/0.6ml, 80mg/0.8ml in ready-to-use pre-filled syringes with safety devices.
• Aspen Holdingsis a multinational pharmaceutical company serving people for over 170 years. The company works in a diverse range of segments including cancer, HIV, tuberculosis, and others. Aspen API provides heparin sodium (9042-08-1) that prevents blood clotting and makes blood thinner.

Key Market Developments

• In November 2022, Techdow USA Inc. launched a heparin sodium injection USP in the USA market. Moreover, the company said to ensure reliable heparin supply in the market with reasonable and competitive pricing.
• In January 2022, Ohio-based biotechnology firm Optimvia developed a cost-effective synthetic method to produce large quantities of heparin. The company agreed with biology firm Ginkgo Bioworks to scale the production process.

Segmentation:

By Type

• Low Molecular Weight Heparin
• Ultra-low Molecular Weight Heparin
• Unfractioned Heparin

By Route

• Intrevenous
• Subcutaneous

By Application

• Atrial Fibrillation
• Renal Impairment
• Coronary Artery Disease
• Others

By End-Use

• Outpatient
• Inpatient

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others